

**Pilocarpine as a treatment option for dupilumab-related eye manifestations**



*To the Editor:* The treatment of atopic dermatitis (AD) has changed dramatically after the development of dupilumab. Despite its good efficacy, AD patients frequently develop blepharoconjunctivitis after the administration of dupilumab. Dupilumab-associated ocular surface disease (DOSD) is one of the most frequently encountered side effects in clinical practice. The incidence of conjunctivitis has been reported to be 8.6 % in the CHRONOS trial and 28% in the LIBERTY AD CAFÉ trial. Although it is usually mild to moderate, it significantly affects the activities of daily living, and some patients develop severe conditions such as cicatrizing conjunctivitis.<sup>1</sup> Ocular manifestations can be managed with eyelid hygiene, artificial tears, antihistamine eye drops, and anti-inflammatory eye drops. However, not all cases respond well to such treatment and some patients discontinued dupilumab due to uncontrolled severe eye manifestations.<sup>2</sup>

We retrospectively analyzed patients who developed blepharoconjunctivitis after being treated with dupilumab. Electromedical records and

photographs were reviewed, and this study was approved by the institutional review board. An ophthalmologist (Dr H.J.B.) determined the severity of conjunctivitis (none, trace, mild, moderate, or severe) based on the intensity of bulbar or palpebral hyperemia.<sup>3</sup> The patients' treatment response after 3 m compared to initial symptoms/signs was analyzed. Complete remission was defined as no symptoms (pain and/or itching) or signs after treatment, remission status was defined as trace conjunctivitis with 75% improved symptoms compared to baseline, stable status was defined as mild conjunctivitis with 50% improved symptoms, and worsened status was defined as moderate or severe conjunctivitis with exacerbation of subjective symptoms. In 143 patients, 31 patients (21.7%) developed ocular complications after dupilumab prescription. Three patients (9.7%) achieved complete remission after treatment, and 14 patients (45.2%) achieved remission status. Ten patients (32.3%) showed stable status compared to baseline, but 4 patients (12.9%) experienced worsening of ocular condition despite treatment (Table I). We found that a significant proportion of patients still suffered from ocular complications even after

**Table I.** Response to conventional treatments in dupilumab-related ocular complications

Treatment profile	Number of cases	Response to treatment			
		Worsened	Stable	Remission	Complete remission
Artificial tear only	1	0	0	0	1
Anti-histamine eye drop (± artificial tear)	9	0	5	4	0
Anti-inflammatory ointment* (± artificial tear & anti-histamine eye drop)	6	0	3	3	0
Anti-inflammatory eye drop† (± artificial tear & anti-histamine eye drop)	12	2	2	6	2
Anti-inflammatory ointment & anti-inflammatory eye drop (± artificial tear & anti-histamine eye drop)	3	2	0	1	0
Total	31	4 (12.9%)	10 (32.3%)	14 (45.2%)	3 (9.7%)
Sub-analysis in pilocarpine cases‡	4	0	1	1	2

\*Anti-inflammatory ointment: Topical steroid or topical calcineurin inhibitor.

†Anti-inflammatory eye drop: Steroid eye drop or cyclosporine eye drop.

‡Pilocarpine 5 mg tablet was additionally prescribed to the four worsened patients who did not show response to conventional treatment, and their response to pilocarpine were categorized.



**Fig 1.** Dupilumab-associated blepharoconjunctivitis. Before prescribing pilocarpine (*left*), and 3 m after initiating pilocarpine (*right*).

treatment. To address this clinical problem, we tried oral pilocarpine 5 mg to the 4 worsened patients who did not experience improvement after conventional treatment, and ocular conditions were remitted in 3 out of 4 patients (Fig 1).

Several mechanisms are thought to be related with the development of DOSD, including increased demodex mites due to altered cytokine activity, increased OX40 ligand activity, eosinophilia, and decreased goblet cells.<sup>1,2</sup> Goblet cells are mucus-secreting cells which are important in the ocular surface barrier, and IL-13 regulates goblet cell proliferation and mucus secretion. Since dupilumab blocks the IL-13 pathway, it may lead to decreased goblet cell density and decreased mucin production, which leads to impaired ocular surface barrier and conjunctival inflammation.<sup>4</sup> In this regard, we thought pilocarpine, a muscarinic agonist which is known to promote the secretion of aqueous tear from conjunctiva, lacrimal glands, and mucin from goblet cells, could be considered as a treatment option for dupilumab-associated blepharoconjunctivitis.<sup>5</sup> Although evidence is limited due to the small number of cases, pilocarpine showed promising results in refractory blepharoconjunctivitis. Further studies are needed to clarify the exact efficacy of pilocarpine in dupilumab-associated blepharoconjunctivitis.

Won Seok Roh, MD,<sup>a</sup> Joo Hee Lee, MD,<sup>a</sup> Su Min Kim, MD,<sup>a</sup> Hyeong Ju Byeon, MD,<sup>b</sup> and Chang Ook Park, MD, PhD<sup>a,c</sup>

From the Department of Dermatology and Cutaneous, Biology Research Institute, Yonsei University College of Medicine, Seoul, Korea,<sup>a</sup> Department of Ophthalmology, Severance Hospital, Institute of Vision Research, Yonsei University College of Medicine, Seoul, Korea,<sup>b</sup> and Institute of Allergy, Yonsei University College of Medicine, Seoul, Korea.<sup>c</sup>

**Funding sources:** This study was supported by a grant from the National Research Foundation of Korea (2020R1A2C1009916).

**Key words:** atopic dermatitis; blepharoconjunctivitis; cholinergic; conjunctivitis; dry eye; dupilumab; IL-13; ocular surface disease; OX40; pilocarpine.

**Correspondence to:** Chang Ook Park, MD, PhD, Department of Dermatology and Cutaneous, Biology Research Institute, Institute of Allergy, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, Korea

**E-mail:** [copark@yuhs.ac](mailto:copark@yuhs.ac)

**Conflicts of interest**

None disclosed.

**REFERENCES**

1. Popiela MZ, Barbara R, Turnbull AMJ, et al. Dupilumab-associated ocular surface disease: presentation, management and long-term sequelae. *Eye (Lond)*. 2021;35:3277-3284.
2. Agnihotri G, Shi K, Lio PA. A Clinician's Guide to the Recognition and Management of Dupilumab-Associated Conjunctivitis. *Drugs R D*. 2019;19:311-318.
3. Craven ER, Liu CC, Batoosingh A, Schiffman RM, Whitcup SM. A randomized, controlled comparison of macroscopic conjunctival hyperemia in patients treated with bimatoprost 0.01% or vehicle who were previously controlled on latanoprost. *Clin Ophthalmol*. 2010;4:1433-1440.
4. Bakker DS, Ariens LFM, van Luijk C, et al. Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis. *Br J Dermatol*. 2019; 180:1248-1249.
5. Shih KC, Lun CN, Jhanji V, Thong BY, Tong L. Systematic review of randomized controlled trials in the treatment of dry eye disease in Sjogren syndrome. *J Inflamm (Lond)*. 2017;14:26.

<https://doi.org/10.1016/j.jdin.2022.06.007>